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Abstract
 .Vascular endothelial growth factor VEGF is a potent mitogen for endothelial cells and a vascular permeability factor.
 .In this study we found that the addition of angiotensin II AII to rat heart endothelial cells induced VEGF mRNA
production. VEGF mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 4 h. The induction
was superinduced by cycloheximide and blocked by actinomycin D. Losartan, an AT receptor antagonist, abolished the1
induction of VEGF mRNA by AII, whereas PD 123319, an AT receptor antagonist, had no effect on VEGF mRNA2
induction. H7, a protein kinase C inhibitor, blocked the induction. RT-PCR experiments showed two mRNA species VEGF
.120 and VEGF 164 in these cells and both species were stimulated by AII. Transient transfection experiment showed that
VEGF promoter activity was increased 2.2-fold upon AII stimulation. Electrophoretic mobility shift assay revealed an
enhanced binding of transcription factors AP-1 and NF-kB. Immunoblot analysis showed that the amount of secreted VEGF
was elevated in the medium 8 h after AII stimulation. Our results demonstrate for the first time that the upregulation of
VEGF by AII may play a significant role in AII-induced hyperpermeability. q 1998 Elsevier Science B.V.
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1. Introduction
VEGF is a potent angiogenic factor and a specific
 w x.mitogen for endothelial cells for reviews, see 1–3 .
It is a heparin-binding, homodimeric protein with Mr
w x40 000–45 000 4 . VEGF is the only growth factor
w xwith vascular permeability activity 5,6 . VEGF is
w xchemotactic 7 and has been shown to induce plas-
minogen activators, plasminogen activator inhibitor
w x w x w x8 , urokinase receptor 9 and collagenase 10 in
)  .Corresponding author. Fax: q1 423 232-6908.
endothelial cells. VEGF is important for normal ves-
sel growth, development, differentiation, wound heal-
ing and reproduction.
Several forms of human VEGF exist as a result of
w xalternative splicing 11,12 . They are VEGF 121, 165,
189, and 206. Murine VEGFs are one amino acid
w xshorter than their human counterpart 13 . VEGF 121
and VEGF 165 are secreted whereas VEGF 189 and
VEGF 206 are sequestered in the cell matrix or
w xbound to cell membranes 14 .
The gene expression of VEGF can be upregulated
w xby a number of effectors such as adenosine 15 ,
w xcAMP analogs 16 , cytokines such as tumor necrosis
w x w xfactor-a 17 , interleukin-1b 18 , transforming
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w xgrowth factor-b1 19,20 or growth promoting agents
w x21–26 in various cell systems including fibroblasts,
epithelial cells, keratinocytes, smooth muscle cells
and several tumor cell lines. Hypoxia has been shown
to be the strongest inducer for VEGF both in vitro
w xand in vivo 27–30 .
w xWiener et al. 31,32 reported that the infusion of
AII to rats could increase the permeability of vessels.
This observation prompted us to examine if the ex-
pression of VEGF is upregulated as a result of AII
treatment in endothelial cells. In this study, we exam-
ined the effect of AII on rat heart-derived endothelial
cells and found that AII was indeed a strong inducer
of VEGF.
2. Materials and methods
2.1. Cell culture and materials
 .Rat heart-derived endothelial cells RHE were
w xprovided by Diglio et al. 33 . Cells were cultured in
Dulbecco’s modified Eagle’s medium DMEM, Life
.Technologies containing 10% fetal bovine serum
 .FBS , 2 mM L-glutamine and 25mgrml gentamycin
at 378C in a humidified atmosphere of 5% CO . Cells2
were serially subcultured by treatment with trypsin
 .0.05% trypsin in 0.5 mM Versene and were used for
experimentation between passages 12 and 25. These
cells exhibited typical ‘‘cobblestone’’ morphology
devoid of any smooth muscle cells. Bovine aortic
endothelial cells were purchased from Cell Systems
 .Kirkland, WA . These cells were cultured in CS-C
medium containing 10% FBS and used for transfec-
tion studies between passages 3 to 6. H7, polydI–
polydC, and salmon testes DNA were obtained from
 . w32 x w 32 xSigma St. Louis, MO . P dCTP and g- P ATP
 .were obtained from ICN Costa Mesa, CA . ITS was
purchased from Collaborative Biomedical Bedford,
.MA . Fetal bovine serum was obtained from Bioflu-
 .ids Rockville, MD . Anti-human VEGF antibody
 .was purchased from PeproTech Rocky Hill, NJ . T4
kinase, luciferase assay kit, DNA size marker, AP-1
and NF-kB consensus oligomers were purchased from
 .Promega Madison, WI . RT-PCR kit was obtained
 .from Perkin-Elmer Foster City, CA . Lipofectamine
was purchased from Life Technologies Gaithersburg,
.MD . All other reagents used were of the highest
grade commercially available.
2.2. Northern blot analysis
Cells were seeded into 100 mm dishes containing
DMEM and 10% FBS. Near confluent cells were
changed to serum-free DMEM supplemented with
ITS 1 mM insulin, 6.25 mgrml transferrin and
.6.25 ngrml selenous acid for 24 h before the addi-
tion of test agents. After the designated time, total
RNA was extracted using the acid guanidinium thio-
w xcyanate–phenol–CHCl extraction method 34 . Fif-3
teen mg of RNA was denatured and separated by
electrophoresis on 1% agarose gel containing 2.2 M
formaldehyde. Following transfer, the RNA was co-
valently bound to GeneScreen NEN Life Science
.Products by UV-crosslinking. Hybridization and
washing conditions were carried out according to the
w xmethod of Church and Gilbert 35 . A human VEGF
cDNA probe was provided by Dr. Donald Torry,
University of Tennessee, Knoxville. The cDNA was
w32 xlabeled with P dCTP using random primer synthe-
sis. The blots were exposed to XAR films with
intensifying screens. The intensity of the bands was
quantitated by Digital Imaging System Alpha In-
.notech . Experiments were repeated at least three
times and representative data were shown.
2.3. RT-PCR analysis of VEGF transcripts
The cDNA was synthesized by reverse transcrip-
 .tion reaction 25ml of 1 mg of total RNA isolated
from RHE cultures treated with or without AII for
2 h. Five ml of cDNA was amplified by Taq DNA
polymerase in a 25ml reaction containing 10 mM
 .Tris–HCl pH 8.3 , 50 mM KCl, 1.5 mM MgCl ,2
0.2 mM dNTP, and 10 pmol of the two primers
 .synthesized by Operon Technologies :
X X  .1. 5 -CCATGAACTTTCTGCTCTCTTG-3 sense
and
X X2. 5 -GGTGAGAGGTCTAGTTCCCGA-3
 .antisense .
The reaction was allowed to proceed for 40 cycles,
each cycle consisting of 45 s at 948C, 35 s at 548C,
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and 45 s of polymerization at 728C and finally a
10 min extension at 728C. Ten ml aliquots of the PCR
reaction were separated on a 2% agarose gel.
2.4. VEGF promoter acti˝ity
 .Bovine aortic endothelial cells BAEC cultures in
60 mm dishes were transfected with 5 mg of a pro-
 .moterless luciferase gene pxp or luciferase gene
containing VEGF promoter 1.6 kb EcoRV-Pst1 se-
quence, gift of Drs. Andrew P. Levy and Mark A.
. w xGoldgerg, Harvard Medical School 36 in the pres-
ence of 13 mg of Lipofectamine according to manu-
facturer’s protocol. After 5 h, the cells were changed
to DMEM containing 10% FBS overnight. The cells
were then incubated in serum-free medium for 8 h
before the addition of 1 mM AII for 36 h. Cultures
were incubated with lysis buffer and luciferase activ-
ity was measured with a kit from Promega. Protein
concentration was determined by BioRad dye binding
assay.
2.5. Nuclear extract and electrophoretic mobility shift
assay
Nuclear extract from control and AII-treated cells
w xwere prepared according to Andrews and Faller 37 .
AP-1 and NF-kB consensus sequences were end
w 32 xlabeled with g P -ATP and T4 kinase. Binding
 .reaction 20 ml containing 5mg of nuclear extract,
1 mg testes DNA, 1 mg polydI–polydC in 10 mM
Hepes, pH 7.9, 10% glycerol, 100 mM NaCl, 0.5 mM
MgCl , 0.8 mM EDTA, 0.2 mM dithiothreitol,2
0.08 mM phenylmethylsulfonyl fluoride, was preincu-
bated at room temperature with or without competi-
tors for 15 min. 32 P-labeled AP-1 or NF-kB
 .90 000 cpm was then added to the reaction and
incubated at room temperature for another 20 min.
The samples were resolved on native 5% polyacryl-
amide gel at 48C with 0.5=TBE 1=TBE: 0.045 M
.Tris–borate, 1 mM EDTA . The gel was dried and
analyzed by autoradiography.
2.6. Immunoblot analysis of VEGF
Near confluent RHE cultures in 100 mm dishes
were incubated with serum-free DMEM supple-
mented with ITS. Cells were treated with or without
AII for designated times. Conditioned media were
collected in the presence of protease inhibitors
2 mgrml aprotinin, 2 mgrml leupeptin and 0.5 mM
.phenylmethylsulfonyl fluoride . Secreted proteins in
the conditioned medium were precipitated with qui-
nine sulfate–SDS according to the method of Werb et
w xal. 38 . The precipitates were resuspended in
Laemmli SDS gel sample buffer and electrophoresed
on 12% SDS-PAGE. Immunoblots were carried out
 .with rabbit anti-human VEGF antibodies 1:500 at
room temperature for 1.5 h and then with goat anti-
rabbit IgG conjugated to alkaline phosphatase
 .1:10 000, Sigma for 1 h. Color reaction was per-
formed with nitroblue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate.
3. Results
Steady-state levels of VEGF mRNA were deter-
mined in RHE cultures by Northern blot analysis.
 .The basal level of VEGF mRNA 3.7 kb was low.
The mRNA level increased rapidly upon the addition
of AII. Levels of VEGF mRNA increased 5-fold at
 . 2 h Fig. 1, lane 4 and then declined over 4 h lane
.6 . As shown in Fig. 2, VEGF mRNA responded to
AII in a dose-dependent manner.
The next series of experiments were performed to
examine the mechanism of VEGF mRNA induction.
Fig. 1. Time course of VEGF mRNA induction in RHE cells by
 y7 .AII. Near confluent cultures were exposed to AII 1=10 M
for the times indicated. Fifteen mg of total RNA was hybridized
with a cDNA probe for human VEGF. Hybridization patterns of
 .  . cells treated with AII for 0 min lane 1 ; 30 min lane 2 ; 1 h lane
.  .  .  .  .3 ; 2 h lane 4 ; 3 h lane 5 ; 4 h lane 6 ; 5 h lane 7 ; are shown.
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Fig. 2. Dose-dependent induction of VEGF mRNA by AII. Near
confluent cultures of RHE cells were treated with 1=10y12 to
1=10y6 M of AII for 2 h. Fifteen mg of total RNA was hy-
bridized with a cDNA probe for human VEGF. Hybridization
 . y12patterns of control cells lane 1 ; cells treated with 1=10 M
 . y11  . y10  .AII lane 2 ; 1=10 M AII lane 3 ; 1=10 M AII lane 4 ;
y9  . y8  . y71=10 M AII lane 5 ; 1=10 M AII lane 6 ; 1=10 M
 . y6  .AII lane 7 ; 1=10 M AII lane 8 ; are shown.
Inhibitors of protein and RNA synthesis were in-
cluded singly or in combination with AII. Cyclohex-
 .imide alone induced VEGF mRNA Fig. 3, lane 3 .
 . Fig. 3. Effect of cycloheximide CHX and actinomycin D Act
.D on the induction of VEGF mRNA by AII. Near confluent
cultures of RHE cells were treated with AII for 2 h in the absence
 .  .or presence of CHX 20 mgrml or Act D 1mgrml . Fifteen mg
of total RNA was hybridized with a human VEGF cDNA probe.
 .Hybridization patterns of control cells lane 1 ; cells treated with
y7  .  .  .1=10 M AII lane 2 ; CHX lane 3 ; AII and CHX lane 4 ;
 .  .Act D lane 5 ; AII and Act D lane 6 ; are shown.
 .In the presence of AII and cycloheximide lane 4 the
 .induction was higher than AII alone lane 2 , imply-
ing that the induction does not require de novo
protein synthesis. In the presence of actinomycin D,
 .the induction was abolished lane 6 , indicating that
de novo RNA synthesis is required.
Losartan, a specific antagonist for AT receptors1
w x39 was included to examine whether the effect of
AII was mediated by AT receptors. In the presence1
of 1 mM losartan, the induction of VEGF mRNA
 .decreased drastically Fig. 4, lane 4 , suggesting that
the induction of VEGF mRNA might be mediated by
AT receptors. Involvement of AT receptors was1 2
investigated by including PD 123319, an AT recep-2
w xtor antagonist 40 . PD 123319 at a concentration of
1mM did not abolish the induction of VEGF mRNA
 .lane 6 , suggesting that AT receptors are not in-2
volved.
The promoter of human VEGF gene has been
w xshown to contain AP-1 sites 11 . We next investi-
gated if AII exerted its effect through a protein kinase
C-dependent pathway. H7, a protein kinase C in-
w xhibitor 41 , was included. In these experiments, cells
Fig. 4. Effect of AII receptor antagonists losartan and PD 123319
on the induction of VEGF mRNA. Total RNA was isolated from
RHE cultures in the absence or presence of the antagonist and
 .AII. Hybridization patterns of control cells lane 1 ; cells treated
y7  .  .with 1=10 M AII lane 2 ; 1mM losartan lane 3 ; 1mM
 .  .losartan and AII lane 4 ; 1mM PD 123319 lane 5 ; 1mM PD
 .123319 and AII lane 6 ; are shown.
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Fig. 5. Effect of protein kinase C inhibitor on the induction of
VEGF mRNA by AII. Near confluent RHE cells were pretreated
with a protein kinase C inhibitor, H7, for 30 min before the
addition of AII for 2 h. Hybridization patterns of control cells
 . y7  .lane 1 ; cells treated with 1=10 M AII lane 2 ; 1mM H7
 .  .lane 3 ; AII and H7 lane 4 ; are shown.
were pretreated with 1 mM H7 for 30 min prior to the
addition of AII. H7 was able to block the induction of
 .VEGF mRNA Fig. 5, lane 4 . Our results suggest
Fig. 6. RT-PCR analysis of the expression of VEGF transcripts.
RT-PCR was performed as described in Section 2. Control and
AII treated RNA samples are presented in lanes 1 and 2, respec-
tively. Lane 3 shows the 100bp DNA ladder. Two VEGF tran-
scripts of 493 and 626bp were detected.
that the effect of AII is mediated by a protein kinase
C-dependent pathway.
RT-PCR experiment showed that VEGF mRNA
subtypes in RHE cultures were 493 and 626 base
 .pairs in length Fig. 6, lane 1 . These two products
 .were enhanced in the presence of AII lane 2 . The
sizes of the mRNA match murine VEGF 120 and
 .VEGF 164 42 .
In order to examine if the induction of VEGF
mRNA is a result of transcriptional activation, trans-
fection experiments were carried out with a construct
containing VEGF promoter and luciferase in the ab-
sence or presence of AII. Since RHE cells were
extremely difficult to transfect, bovine aortic endothe-
lial cells were used for these studies. These cells
exhibited similar response to AII and were available
in younger passages. Fig. 7 shows that AII increased
luciferase activity of VEGF gene by 2.2-fold, whereas
AII had minimal effect on the luciferase gene itself.
To characterize the transcription factors that were
activated by AII treatment, EMSA was performed on
Fig. 7. Stimulation of VEGF promoter activity by AII. BAEC
cultures in 60 mm plates were transfected with 5mg of promoter-
less luciferase gene or luciferase gene containing VEGF sequence
and 13mg of Lipofectamine as described in Section 2. Luciferase
activity in the cell lysates was determined by a kit from Promega
and expressed as light units =103rmg protein. Results were
expressed as mean " SEM of three plates for each variable.
Statistical analysis was made by Student’s t test. a P -0.05 vs.
control.
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Fig. 8. AII induced activation of AP-1 and NF-kB binding.
Nuclear extracts from control and AII treated RHE cells were
incubated with labeled oligomer containing an AP-1 binding site
 .  .panel A or an NF-kB binding site panel B . Gel shift patterns
 .of nuclear extract from control cells lane 1 and cells treated
y7  .with 1=10 M AII for 30 min lane 2 , are shown. Lanes 3 and
4 represent the pattern in the presence of 200-fold excess cold
oligomer.
nuclear extracts prepared from RHE cultures treated
with AII. Binding of both AP-1 and NF-kB were
activated by AII in a time dependent manner. AP-1
and NF-kB bands increased slightly after 15 min of
AII stimulation, peaked at 30 min and declined at
 .60 min results not shown . The binding pattern of
 .  .AP-1 panel A and NF-kB panel B 30 min after
 .AII stimulation is shown in Fig. 8 lanes 1 and 2 .
Fig. 9. Appearance of VEGF in the conditioned medium of RHE
cells. Cells were treated with or without AII for different times
and the conditioned medium was precipitated with quinine sul-
fate-SDS. Proteins were separated by 12% SDS-PAGE under
non-reducing conditions. Immunoblot was carried out with rabbit
anti-human VEGF antibodies as described in Section 2. The
 .immunostaining patterns of control cells lane 1 ; cells treated
 .  .with AII for 4 h lane 2 ; 8 h control lane 3 ; cells treated with
 .  .AII for 8 h lane 4 ; 12 h control lane 5 ; and cells treated with
 .AII for 12 h lane 6 ; are shown.
The specificity of the assay was demonstrated by the
disappearance of AP-1 and NF-kB bands after the
addition of excess unlabeled oligomers lanes 3 and
.4 .
In order to examine if the increase of VEGF
mRNA correlates well with the appearance of VEGF
in the conditioned medium, immunoblot analysis was
 .carried out Fig. 9 . The conditioned media of control
and AII-treated cells were precipitated by quinine
sulfate–SDS. Concentrated proteins were displayed
on SDS-PAGE under non-reducing conditions. In the
absence of AII, RHE cells secreted only trace amount
 .of two VEGF bands M 42 000 and 45 000 . Ther
intensity of these bands was increased from 8 to 12 h
 .after the addition of AII lanes 4 and 6 .
4. Discussion
Previously, endothelial cells were thought to re-
spond to VEGF in a paracrine manner. Recently, a
number of endothelial cells were found to express
w xand secrete VEGF 42–44 . The present study
demonstrated that AII acts on rat heart endothelial
cells to induce VEGF mRNA in a dose and time
dependent manner. The induction is mediated by AT1
receptors and involves a protein kinase C dependent
pathway. In addition, the increase of VEGF mRNA
correlated well with the release of VEGF into the
conditioned medium.
Our data demonstrated that the induction of VEGF
mRNA level by AII could be mainly attributed to
transcriptional activation. Electrophoretic mobility
shift assay showed that AII enhanced AP-1 and NF-
kB binding. The promoters of human and mouse
VEGF genes were shown to contain AP-1 and NF-kB
w xbinding sites, respectively 11,45 . Detailed studies
are needed to examine which transcription factors are
functionally important in AII-induced VEGF gene
expression.
It is interesting to note that VEGF mRNA is
‘‘superinduced’’ in the presence of cycloheximide
and AII. The level of VEGF mRNA in the presence
of cycloheximide alone is higher than the basal level.
Cycloheximide might inhibit the synthesis of either
labile ribonucleases that are involved in degrading
 .VEGF mRNA or repressor protein s involved in the
regulation of VEGF gene expression.
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We previously reported that AII induced TGF-b1
w xmRNA in rat heart endothelial cells 46 . Since TGF-
b1 has been demonstrated to induce VEGF in several
w xcell types 18,19 , a question arises as to whether the
increase of VEGF level observed in this study is a
result of the secondary effect of TGF-b1. Two lines
of evidence appear to negate this possibility. First,
the kinetics of induction of VEGF mRNA precedes
that of TGF-b1. Secondly, the released TGF-b1 was
w xfound to be in the latent form by bioassays 46 .
The most important finding of the present study is
the rapid induction of VEGF by AII in rat heart
endothelial cells. Our results could partly explain the
morphological observations made by Wiener et al.
w x31,32 and immunostaining studies of Ratajska et al.
w x47 that AII increased vessel permeability. Because
VEGF is shown to cause endothelial cells to prolifer-
w xate after vascular injury 48 , the induction of VEGF
as a result of AII stimulation may also play a role in
wound repair. In conclusion, VEGF induced by AII
may play an important role in the change of endothe-
lial cell permeability and angiogenesis in renovascu-
lar hypertension.
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